References
- GreenMFKernRSBraffDJMintzJNeurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?Schizophr Bull200026111913610755673
- GoldbergTEGoldmanRSBurdickKECognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Arch Gen Psychiatry200764101115112217909123
- KeefeRSHarveyPDCognitive impairment in schizophreniaHandb Exp Pharmacol2012213113723027411
- PreskornSHGawrylMDgetluckNPalfreymanMBauerLOHiltDCNormalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophreniaJ Psychiatr Pract2014201122424419307
- RibeizSRBassittDPArraisJAAvilaRSteffensDCBottinoCMCholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literatureCNS Drugs201024430331720297855
- AmentaFTayebatiSKPathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunctionCurr Med Chem200815548849818289004
- PohankaMAlpha-7 Nicotinic acetylcholine receptor is a target in pharmacology and toxicologyInt J Mol Sci20121322219223822408449
- Di SantoSGPrinelliFAdorniFCaltagironeCMusiccoMA meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer’s diseaseJ Alzheimers Dis201335234936123411693
- BuchananRWConleyRRDickinsonDGalantamine for the treatment of cognitive impairments in people with schizophreniaAm J Psychiatry20081651828917986678
- LindenmayerJPKhanAGalantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophreniaSchizophr Res20111252–326727720850275
- KeefeRSMalhotraAKMeltzerHYEfficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trialNeuropsychopharmacology20083361217122817625502
- EricksonSKSchwarzkopfSBPalumboDBadgley-FleemanJSmirnowAMLightGAEfficacy and tolerability of low-dose donepezil in schizophreniaClin Neuropharmacol200528417918416062097
- TriccoACSoobiahCBerlinerSEfficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysisCMAJ2013185161393140124043661
- KumariV1PostmaPNicotine use in schizophrenia: the self medication hypothesesNeurosci Biobehav Rev20052961021103415964073
- ThakurathiNVincenziBHendersonDCAssessing the prospect of donepezil in improving cognitive impairment in patients with schizophreniaExpert Opin Investig Drugs2013222259265
- KaySRFiszbeinAOplerLAThe Positive and Negative Syndrome Scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
- GuoXZhaiJLiuZEffect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year studyArch Gen Psychiatry201067989590420819983
- WechslerDWMS-R: Wechsler Memory Scale-Revised: ManualSan Antonio, TX, USAPsychological Corporation1987
- BrandtJBenedictRHBHopkins Verbal Learning Test-Revised: Professional ManualLutz, FL, USAPsychological Assessment Resources2001
- BenedictRBrief Visuospatial Memory Test-Revised: Professional ManualOdessa, FL, USAPsychological Assessment Resources1997
- ReitanRMWolfsonDThe Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation2nd edSouth Tucson, AZ, USANeuropsychology Press1997
- KeefeRSBrief Assessment of Cognition in Schizophrenia (BACS) Manual-A. Version 21Durham, NC, USADuke University Medical Center1999
- SpreenQStraussEA Compendium of Neuropsychological Tests: Administration, Norms, and Commentary2nd edNew York, NY, USAOxford University Press1998
- CornblattBARischNJFarisGFriedmanDErlenmeyer-KimlingLThe Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal familiesPsychiatry Res19882622232383237915
- HeatonRKWisconsin Card Sorting Test Manual: Revised and ExpandedLutz, FL, USAPsychological Assessment Resources1993
- GoldenCJStroop Color and Word Test: A Manual for Clinical Experimental UsesWood Dale, IL, USAStoelting Co1978
- KeefeRSSweeneyJAGuHEffects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparisonAm J Psychiatry200716471061107117606658
- GuyWECDEU Assessment Manual for PsychopharmacologyRockville, MD, USAUS Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration1976
- AddingtonDAddingtonJMaticka-TyndaleEAssessing depression in schizophrenia: the Calgary Depression ScaleBr J Psychiatry Suppl19932239448110442
- SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
- LaneRDGlazerWMHansenTEBermanWHKramerSIAssessment of tardive dyskinesia using the Abnormal Involuntary Movement ScaleJ Nerv Ment Dis198517363533573998720
- CohenJA power primerPsychol Bull1992112115515919565683
- BilderRMGoldmanRSRobinsonDNeuropsychology of first episode schizophrenia: initial characterization and clinical correlatesAm J Psychiatry2000157454955910739413
- KrishnadasRJauharSTelferSShivashankarSMcCreadieRGNicotine dependence and illness severity in schizophreniaBr J Psychiatry2012201430631222878134
- WintererGWhy do patients with schizophrenia smoke?Curr Opin Psychiatry201023211211920051860
- BarnesMLawfordBRBurtonSCSmoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?Aust N Z J Psychiatry2006406–757558016756583
- KumariVPostmaPNicotine use in schizophrenia: the self medication hypothesesNeurosci Biobehav Rev20052961021103415964073
- FureyMLPietriniPHaxbyJVCholinergic enhancement and increased selectivity of perceptual processing during working memoryScience200029055002315231911125148
- CrookJMTomaskovic-CrookECopolovDLDeanBDecreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formationBiol Psychiatry200048538138810978721
- BreeseCRLeeMJAdamsCEAbnormal regulation of high affinity nicotinic receptors in subjects with schizophreniaNeuropsychopharmacology200023435136410989262
- FreedmanRHallMAdlerLELeonardSEvidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophreniaBiol Psychiatry199538122337548469
- GuanZZZhangXBlennowKNordbergADecreased protein level of nicotinic receptor alpha-7 subunit in the frontal cortex from schizophrenic brainNeuroreport19991081779178210501574
- PowchikPDavidsonMHaroutunianVPostmortem studies in schizophreniaSchizophr Bull19982423253419718627
- TsunoNDonepezil in the treatment of patients with Alzheimer’s diseaseExpert Rev Neurother20099559159819402770
- WangCYXiangYTWengYZCigarette smoking in patients with schizophrenia in China: prospective, multicentre studyAust N Z J Psychiatry201044545646220397788